DOCSLIB.ORG

Employee Selectionpdf1.3 MB

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Employee Selectionpdf1.3 MB Employee selection Please note: this PDF contains only the pages highlighted in the list of contents below. The contents of this file are qualified in their entirety by reference to the printed version of the Philips Annual Report 2019. The information in this PDF has been derived from the audited financial statements 2019 of Koninklijke Philips N.V. Ernst & Young Accountants has issued unqualified auditors’ reports on these financial statements. IFRS basis of presentation The financial information included in this document is based on IFRS, as explained in Significant accounting policies, of the Annual Report 2019, unless otherwise indicated. Forward-looking statements This document contains certain forward-looking statements. By their nature, these statements involve risk and uncertainty. For more information, please refer to Forward-looking statements and other information, starting on page 59 References to Philips References to the Company or company, to Philips or the (Philips) Group or group, relate to Koninklijke Philips N.V. and its subsidiaries, as the context requires. Royal Philips refers to Koninklijke Philips N.V. Philips Lighting/Signify References to 'Signify' in this Annual Report relate to Philips' former Lighting segment (prior to deconsolidation as from the end of November 2017 and when reported as discontinued operations), Philips Lighting N.V. (before or after such deconsolidation) or Signify N.V. (after its renaming in May 2018), as the context requires. Dutch Financial Markets Supervision Act This document comprises regulated information within the meaning of the Dutch Financial Markets Supervision Act (Wet op het financieel toezicht). Statutory financial statements and management report The chapters Group financial statements and Company financial statements contain the statutory financial statements of the Company. The introduction to the chapter Group financial statements sets out which parts of this Annual Report form the Management report within the meaning of Section 2:391 of the Dutch Civil Code (and related Decrees). Front cover: In 2019, Philips unveiled a unique augmented-reality concept developed with Microsoft Corp. to intuitively control the operating room of the future, giving doctors a holographic dashboard of data that integrates imaging, device and medical information to drive treatment optimization. This solution capitalizes on the advanced, integrated capabilities of Philips’ industry-leading Azurion image-guided therapy platform and is being used to gather clinical insights to support a future commercially available product. Contents 1 Message from the CEO 4 4 Financial performance 22 4.1 Performance review 22 2 Board of Management and Executive 7 4.2 Investor information 34 Committee 5 Societal impact 37 3 Strategy and Businesses 8 5.1 Social performance 37 3.1 Innovating with purpose 8 5.2 Environmental performance 42 3.2 How we create value 10 3.3 Our businesses 12 6 Supervisory Board 49 3.4 Quality, Regulatory Compliance and Integrity 20 Message from the CEO 1 1 Message from the CEO “Philips continues to make progress to unlock its full potential as a leader in health technology. Our innovations are driving better health outcomes and increased healthcare productivity, while offering a better experience for consumers, patients and healthcare professionals.” Frans van Houten, CEO Royal Philips Dear Stakeholder, In 2019, we continued our transformation as a focused outcomes and productivity gains, as well as extending leader in health technology, pursuing our vision of access to care to those in need. making the world healthier and more sustainable through innovation. I am pleased with the resilience of Our goal of improving the lives of 3 billion people a year our businesses as we recorded 4.5% growth while by 2030, including 400 million in underserved addressing significant headwinds. We made good healthcare communities, infuses our innovation drive progress against our strategic imperatives – driving with true purpose, as we strive to make the world customer centricity and operational excellence, healthier and more sustainable, in line with UN focusing on quality, growing our core businesses, and Sustainable Development Goals 3 (Ensure healthy lives pivoting to become a solutions company. Our purpose and promote well-being for all at all ages), 12 (Ensure is clear, and so is our firm belief in our potential to grow sustainable consumption and production patterns) and and create more value, while doing so in a sustainable 13 (Take urgent action to combat climate change and manner. Reflecting our confidence in the road ahead its impacts). and the importance we attach to dividend stability, we propose to maintain the dividend at EUR 0.85 per share. Innovating with purpose in mind helps us to create more value for our customers and society – by Innovating with purpose developing truly relevant solutions. Helping people to Time and again, customers tell us they like our strategy stay healthy and prevent disease. Giving clinicians the and the comprehensive view we take of healthcare AI-assisted tools to make precision diagnoses and along the health continuum – delivering innovations for deliver personalized, minimally invasive treatment. consumer health, precision diagnosis, image-guided Orchestrating and delivering care outside the hospital, therapy, hospital and home care, leveraging informatics in lower-cost care settings. Helping people to recover, and artificial intelligence. They are keen to engage with or live with chronic disease, at home in the community. Philips for innovations that can help them deliver on the All supported by a seamless flow of data enabled by Quadruple Aim – better health outcomes, improved connected care and health informatics solutions. patient and staff xperience e, and lower cost of care. This is reflected in the sustained growth in the number Increasingly, AI will enhance the quality and efficiency of long-term strategic partnerships we have signed, e.g. of care, providing clinical decision support, helping with Inspira Health (USA) and Klinikum Stuttgart clinical staff ot spot emerging risks, and freeing up (Germany), with solutions and recurring revenues now valuable time for healthcare professionals to focus on accounting for over one third of total revenues. There is their patients. We work with clinical partners around the also substantial interest in how we can contribute to world to develop AI-enabled solutions, like our care outside the hospital setting – through solutions IntelliSpace AI Workflow Suite, that are secure, firmly that support healthy living, prevention and home care. grounded in scientific esearr ch, and rigorously validated in clinical practice. Aging populations and the growing incidence of chronic disease, coupled with resource constraints, are In the consumer domain too, connected personal necessitating a shift from a volume-based approach health solutions like our Philips Sonicare Teledentistry towards value-based healthcare models, including care service help people to manage their health with outside of the hospital. I firmly believe that innovative actionable insights, coaching, and where needed, health technology – a growing market with scope for support from care professionals. margin expansion, in which Philips has strong positions – will help address these challenges, providing better 4 Annual Report 2019 Message from the CEO 1 Determined to deliver the full benefits of data-enabled diagnostic informatics, the latter strengthened by the care, we have significantly stepped up our activities in recent acquisition of Carestream Health’s Healthcare informatics and data science in recent years. Today, Information Systems business. around one in two Philips R&D professionals is active in these fields, and most of our acquisitions since 2015 Our Connected Care businesses had a challenging year, have been designed to strengthen our informatics even as we retained market share. The businesses capabilities. posted modest growth, though profitability decreased. The fundamentals remain solid – our Connected Care As a purpose-led innovation company, we have made businesses have leading market positions and good sustainability a cornerstone of the way we do business, scope for margin expansion. We have taken decisive as recognized once again in the global 2019 Dow Jones actions and expect these to gradually become visible in Sustainability Indices (DJSI) list. Increasingly, our performance in the course of 2020. In January 2020, I customers ask us to help them tackle their sustainability appointed Roy Jakobs as the new leader of the challenges; we believe that, more and more, this will Connected Care businesses to further drive the become a competitive differentiator. In 2019, we took turnaround. Several new innovations – such as the another step closer to becoming carbon-neutral in our next-generation IntelliVue MX750 and MX850 patient own operations by the end of 2020, with both our US monitors, our expanded SmartSleep solutions, the and Dutch facilities now 100%-powered by renewable latest iteration of our IntelliSpace Enterprise Edition energy. We also issued our first Green Innovation Bond healthcare informatics platform, and our HealthSuite under the Philips Green & Sustainability Innovation digital ecosystem – will support accelerated growth, Bond Framework developed together with Rabobank; while stronger execution will help improve value the proceeds will be used to help finance our creation. expenditures on green
Load more

Recommended publications
  • (2) January 2020 CVJ.Pmd
    DOI: https://doi.org/10.3329/cardio.v12i2.47994 Special Article Clarence Walton Lillehei: The Pioneer Open Heart Surgeon Md Anisuzzaman, Nazmul Hosain Department of Cardiac Surgery, Chattogram Medical College Key Words : (Cardiovasc. j. 2020; 12(2): 145-148) Walton Lillehei, Open heart surgery. Introduction: Wangensteen provided a creative environment that Heart as an organ was always a difficult territory produced many brilliant surgeons, and he took a for the surgeons. Famous surgeon Stephen Paget special interest in young Lillehei. in 1895 wrote, “Surgery of the heart has probably In 1949, Dr. Lillehei was appointed a fulltime reached the limit set by the nature, no new instructor of surgery at the University of methods, and no new discovery can overcome the Minnesota Medical School. He began to work his natural difficulties that attend a wound of the way up the academic ladder towards a clinical heart”. But surgeons like Axel Cappelen of Norway professorship. The following year, however fate in 1895, Ludwig Rehn of Germany in 1896 did the dealt him a cruel blow: he was diagnosed with job very well by repairing stab injuries of the heart. lymphosarcoma of the parotid gland and was given But these were rare achievements. Virtually there at most, a 10% chance of surviving for 5 years. was no safe surgical approach or method to deal The day after he finished his senior residency, the heart well before the 1950s. C W Lillehei and Lillehei underwent extensive head and neck his colleagues brought about these changes to surgery at the hands of Dr. Wangensteen and Dr.
    [Show full text]
  • EIR) Expertise Guide
    v MEDICAL INDUSTRY LEADERSHIP INSTITUTE 2019–2020 Executive in Residence (EIR) Expertise Guide John J. Alexander, ChEng, MDA [email protected] President, Business Development Advisors, Inc.; Chairman, Twin Cities Angels Funds Roles: Corporate Development, CEO, Management Team Coach Background: St. Jude Medical, Baxter Healthcare, W.R. Grace, GE, Alcoa. Private companies—Wide Range Expertise: (Markets) Medical Technology: devices, diagnostics (Functions) Corporate Development: M&A, strategic alliances, divestitures, licensing, corporate ventures, internal startups starting, building emerging technology businesses and turning-around established businesses; (Functions) venture capital & angel capital, PIPE, venture debt, debt Susan Alpert, PhD, MD [email protected] Principal, SFA Consulting Roles: Regulatory affairs, device evaluation, pediatrician with specialty in infectious disease Background: Medtronic, C.R. Bard, FDA Expertise: Regulatory affairs, FDA, clinical trials, medical devices, business strategy Daniel L. Cosentino, MBA [email protected] CEO, ElectroSea ROLES: CEO, Entrepreneur, Board Advisor, Investor BACKGROUND: Founder & CEO, Cardiocom; VP/GM, Medtronic; Board Advisor, Minnetronix Neuro EXPERTISE: Digital health, medical devices, entrepreneurship, new product development, general management Michael Finch, PhD [email protected] Research Manager, Children’s Hospital MN Roles: Faculty, instructor, research director Background: Carlson School of Management, Children’s Hospital, School of Public Health, UMN, UnitedHealth Group Expertise: Cost, quality and financing of health care in public and private market, research methods and evaluation, valuation of medical innovations, hospital safety, role of physician communication in health care Paul J. Gam, MBA, CGMA, CPA (Inactive) [email protected] Founder and CEO, Zurich Medical Roles: Various management and advisory roles Background: Founder and CEO, Zurich Medical; Board Member, Blue Cross Blue Shield of MN; Partner, Grace Associates; VP International Development, St.
    [Show full text]
  • Executive Compensation 14 ITEM 12
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A (Amendment No. 1) ☑ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2016 OR ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission file number 333-199861 MYLAN N.V. (Exact name of registrant as specified in its charter) The Netherlands 98-1189497 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Building 4, Trident Place, Mosquito Way, Hatfield, Hertfordshire, AL10 9UL, England (Address of principal executive offices) +44 (0) 1707 853 000 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class: Name of Each Exchange on Which Registered: Ordinary shares, nominal value €0.01 The NASDAQ Stock Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☑ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☑ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Digital Pathology: the Dutch Perspective
    Digital pathology: The Dutch perspective Paul J van Diest, MD, PhD Professor and Head, Department of Pathology University Medical Center Utrecht PO Box 85500, 3508 GA Utrecht The Netherlands [email protected] Professor of Oncology Johns Hopkins Oncology Center Baltimore, MD, USA Notice of Faculty Disclosure In accordance with ACCME guidelines, any individual in a position to influence and/or control the content of this ASCP CME activity has disclosed all relevant financial relationships within the past 12 months with commercial interests that provide products and/or services related to the content of this CME activity. The individual below has responded that he/she has no relevant financial relationship(s) with commercial interest(s) to disclose: Paul J. van Diest, MD, PhD Disclosures • member of advisory boards of Roche, Sectra, Philips (unpaid) • client of Hamamatsu, Sectra, Visiopharm, Leica, Aurora, Philips (paying heavily) • test scanners from Philips and Roche (no contract, no fee) • joint research projects with Philips UMCU Why The Netherlands? • “bunch-a-crazy dudes” • innovation is our middle name • not bound by too many rules and EU-FDA • strong believe in advantages in digital pathology Advantages of digital pathology • no more case assembly in the lab efficacy • quicker diagnostics efficacy • easy and more accurate measurements and counting patient safety/efficacy • better overview of tissue present patient safety • flagging missing slides patient safety • tracking viewing patient safety • automatic linking of images/reporting/LMS
    [Show full text]
  • Royal Philips First Quarter 2016 Results Information Booklet
    Royal Philips First Quarter 2016 Results Information booklet April 25th, 2016 1 Important information Forward-looking statements This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about our strategy, estimates of sales growth, future EBITA and future developments in our organic business. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements. These factors include, but are not limited to, domestic and global economic and business conditions, developments within the euro zone, the successful implementation of our strategy and our ability to realize the benefits of this strategy, our ability to develop and market new products, changes in legislation, legal claims, changes in exchange and interest rates, changes in tax rates, pension costs and actuarial assumptions, raw materials and employee costs, our ability to identify and complete successful acquisitions and to integrate those acquisitions into our business, our ability to successfully exit certain businesses or restructure our operations, the rate of technological changes, political, economic and other developments in countries where Philips operates, industry consolidation and competition. As a result, Philips’ actual future results may differ materially from the plans, goals and expectations set forth in such forward-looking statements.
    [Show full text]
  • Final Programme CONTENT
    48th EDTNA/ERCA International Conference September 14th-17th, 2019 Prague, Czech Republic Conference Theme New Pathways in the Renal Setting-Caring Together by Integrating Modern Technology based on Knowledge & Education Final Programme CONTENT Welcome Message from the President 3 Acknowledgement – Corporate Members 4 Acknowledgement – Conference Support 5 EDTNA/ERCA Booth 6 Conference Accreditation 6 The Conference Application – Instructions and Logistics 7 Conference Venue – Floor plans 8 Programme at a Glance 9 Scientific Programme Highlights 11 Scientific Programme 14 List of E-Posters 24 The Exhibition Floor Plan 30 The Exhibitors 31 Practical Conference Information 36 Opening Hours Summary 38 Good to know about Prague 38 Conference Contacts 39 2 WELCOME MESSAGE FROM THE PRESIDENT Dear Colleagues, We are very happy to welcome you to Prague for the 48th EDTNA/ERCA Conference. Last time the Conference was held in Prague was in 2008, now, 11 years later we are back in Prague. The Scientific Programme is well prepared and there will be several Workshops, Educational Sessions and Poster sessions. New this year are the Courses which will be interactive sessions allowing everybody to share their expertise. We are, as an Association, in the forefront of Online Communication and it has been a focus for some years and will continue to be one of our focuses for the coming years. Take the opportunity to download the Conference App. It works both for iPhones and Androids. We should never forget that face to face meetings gives us so much more than just to be in a Video call. It has an important role of educating, exchanging information and experience, utilizing the expertise of all of us i.e.
    [Show full text]
  • Connectivity. Access to the Data You Need
    CONNECTIVITY. ACCESS TO THE DATA YOU NEED. Integrate across systems with INVOS™5100C cerebral/ somatic oximetry and BIS™ brain monitoring system. We understand your need for easy access to critical patient Connect to patient monitoring systems for better information — and that requires connectivity to standardized visibility of comprehensive patient data electronic medical record (EMR) systems. Our connectivity ™ ™ ™ solutions integrate vital patient data from INVOS cerebral/ INVOS and BIS monitoring systems connect to a variety ™ of multi-parameter monitors, such as Philips patient somatic oximetry and BIS brain monitoring systems into a ™* ™* variety of clinical information and EMR systems. monitoring systems, using Philips VueLink or IntelliBridge interface solutions. Connect to EMR systems for integrated patient data Additional patient monitoring systems compatible with ™ ™ INVOS™ and BIS™ patient monitoring systems are compatible INVOS and/or BIS monitoring systems include: with most EMR and third-party middleware integration systems INVOS™ cerebral/somatic oximetry system in use today, such as: ∙ Philips EMR ∙ Drägerwerk AG & Co. KGaA ∙ Olympus ∙ Cerner ∙ Nihon Kohden ∙ Surgical Information Systems ∙ Epic ∙ Mindray ∙ SAFERsleep ∙ McKesson ∙ Fukuda Denshi ∙ Siemens ∙ AGFR Health Care ∙ Hewlett Packard Theronyz ∙ ORBIS ∙ ™* ∙ Agilent ∙ Philips VISICU ∙ Allscripts ™ ™* BIS brain monitoring system Philips Emergin ∙ Daintel ∙ Middleware ∙ Philips ∙ DocuSys ∙ Nanthealth (iSirona) ∙ Drägerwerk AG & Co. KGaA ∙ Emergisoft ∙ Nihon Kohden General Electric ∙ Capsule Tech ∙ ∙ GE Healthcare ∙ Meditech ∙ Fukuda Denshi Connect to information management systems for Connect to VGA monitors for simultaneous viewing comprehensive clinical records A VGA port on the INVOS™ monitoring system allows the Clinical data management systems such as Anesthesia INVOS™ monitor screen to be displayed on any external Information Management Systems (AIMS), Clinical VGA monitor.
    [Show full text]
  • Philips 2017 Annual Report
    Investor Relations 15.1 In 2017, a dividend of EUR 0.80 per common share was Exchange rate (based on the “Noon Buying Rate”) EUR per USD paid in cash or shares, at the option of the shareholder. 2013 - 2017 For 48.3% of the shares, the shareholders elected for a period end average high low share dividend, resulting in the issue of 11,264,163 new 2013 0.7257 0.7532 0.7828 0.7238 common shares, leading to a 1.2% dilution. EUR 384 2014 0.8264 0.7533 0.8264 0.7180 million was paid in cash. See also section 3.5, Proposed 2015 0.9209 0.9018 0.9502 0.8323 distribution to shareholders, of this Annual Report. 2016 0.9477 0.9037 0.9639 0.8684 2017 0.8318 0.8867 0.9601 0.8305 ex-dividend date record date payment date Exchange rate per month (based on the “Noon Buying Euronext Rate”) EUR per USD Amsterdam May 7, 2018 May 8, 2018 June 6, 2018 2017 - 2018 New York highest rate lowest rate Stock Exchange May 7, 2018 May 8, 2018 June 6, 2018 August, 2017 0.8545 0.8316 September, 2017 0.8513 0.8305 October, 2017 0.8636 0.8441 Philips Group November, 2017 0.8638 0.8378 Dividend and dividend yield per common share 2008 - 2018 December, 2017 0.8529 0.8318 January, 2018 0.8388 0.8008 5.1% 4.6% 3.4% 3.3% 3.8% 3.3% 3.4% 2.4% 3.0% 2.8% 2.5% Yield in %1) Unless otherwise stated, for the convenience of the 2) 0.80 0.80 0.80 0.80 0.80 Dividend per reader, the translations of euros into US dollars 0.75 0.75 0.75 0.70 0.70 0.70 share in EUR appearing in this section have been made based on the closing rate on December 31, 2017 (USD 1 = EUR 0.8365).
    [Show full text]
  • ASN Kidney Week 2020 Reimagined: Disclosures Page 1
    10/14/2020 ASN Kidney Week 2020 Reimagined: Disclosures Page 1 Last Name First Name Nothing Employer Consultancy Ownership Interest Research Funding Honoraria Patents or Inventions Scientific Advisor or Membership Speakers Bureau Other Interests or Relationships to Disclose Abdel-Kader Khaled Vanderbilt University Medical Center BMC Nephrology; CJASN NKF Education committee; NIDDK Health IT work group Abudayyeh Ala University of Texas MD Anderson Cancer Center Adler Sharon Retrophin; Bristol Myers Squibb; Bayer; Retrophin; Bayer; ChemoCentryx; Omeros; Zyversa Bayer; Zyversa; Retrophin; AstraZeneca; Morphosys Retrophin; Bayer Pharmaceuticals; Zyversa; KDIGO; KRN; NephCure Kidney International AstraZeneca; ChemoCentryx; Omeros; Zyversa; Therapeutics; Calliditas; Morphosys AstraZeneca; Morphosys Foundation; Karger Publishers Morphosys; Karger Afkarian Maryam University of California, Davis Afrouzian Marjan University of Texas Medical Branch Alexion Pharmaceuticals; Banff Foundation Afshinnia Farsad Agarwal Anupam University of Alabama at Birmingham Dynamed - review content related to AKI for Goldilocks Therapeutics Genzyme/Sanofi Fabry Fellowship Award Univ Southern California, Vanderbilt, Emory, Akebia Editorial Board of AJP Renal, Kidney Int and My wife, Lisa Curtis, will be President-elect Dynamed and review updated materials prepared by Lab Investigation; invited to serve on for Women in Nephrology (2018-2019). Dynamed editorial team for AKI topics. Akebia - Advisory board of Goldilocks Therapeutics, Expert Panel to review new therapeutics
    [Show full text]
  • Medtronic 2015 Integrated Performance Report
    FURTHER, TOGETHER 2015 INTEGRATED PERFORMANCE REPORT TABLE OF CEO LETTER …………………………………………………………………………………………………………………………………… 3 CONTENTS COMPANY OVERVIEW ……………………………………………………………………………………………………………………… 5 SUSTAINABiliTY RisK AND OppORTUNITY ……………………………………………………………………………………… 7 VALUE TO SOCIETY ……………………………………………………………………………………………………………………… 10 ACCEss …………………………………………………………………………………………………………………………………… 11 PATIENT SAFETY …………………………………………………………………………………………………………………… 20 FiNANCIAL STRENGTH …………………………………………………………………………………………………………… 25 COMMUNITY INVESTMENTS …………………………………………………………………………………………………… 34 WORKING RESPONSIBLY ……………………………………………………………………………………………………………… 40 GOVERNANCE AND ENGAGEMENT ………………………………………………………………………………………… 41 EMplOYEES …………………………………………………………………………………………………………………………… 49 ENVIRONMENT ……………………………………………………………………………………………………………………… 59 SUPPLY CHAIN ………………………………………………………………………………………………………………………… 65 AWARDS AND RECOGNITION ………………………………………………………………………………………………… 68 FY15 DATA SUMMARY …………………………………………………………………………………………………………………… 69 ABOUT THis REPORT …………………………………………………………………………………………………………………… 74 GlOBAL REPORTING INITIATIVE INDEX ………………………………………………………………………………………… 77 COVER PHOTO: Read Hina’s Story on page 11. MEDTRONIC 2015 INTEGRATED PERFORMANCE REPORT | TABLE OF CONTENTS 2 Since our early days as a company, the Medtronic Mission has remained the same: to alleviate pain, restore health, and extend life for people around the world. We have worked hard to be at the forefront of medical technology innovation, challenging ourselves to develop high-quality
    [Show full text]
  • 1 in the United States District Court for the Eastern
    Case 2:08-cv-00260-DF Document 1 Filed 06/30/08 Page 1 of 7 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF TEXAS MARSHALL DIVISION CARDIO ACCESS LLC, § § Plaintiff, § § v. § CIVIL ACTION NO. 2:08-cv-260 § BOSTON SCIENTIFIC CORPORATION; § JURY TRIAL DEMANDED BOSTON SCIENTIFIC SCIMED, INC.; § CORDIS CORPORATION; § ETHICON, INC.; JOHNSON & JOHNSON; § MEDTRONIC, INC.; MEDTRONIC USA, § INC.; MEDTRONIC VASCULAR, INC.; § KYPHON, INC.; EDWARDS § LIFESCIENCES CORPORATION; and § EDWARDS LIFESCIENCES LLC, § § Defendants. § PLAINTIFF’S ORIGINAL COMPLAINT Plaintiff CARDIO ACCESS LLC files this Original Complaint against the above-named Defendants, alleging as follows: I. THE PARTIES 1. Plaintiff CARDIO ACCESS LLC (“Cardio Access”) is a Texas limited liability company. Cardio Access has its principal place of business in Newport Beach, California and maintains a place of business in Frisco, Texas. 2. Defendant BOSTON SCIENTIFIC CORPORATION (“BSC”) is a Delaware corporation with its principal place of business at One Boston Scientific Place, Natick, Massachusetts 01760. BSC can be served with process through its registered agent, Corporation Service Company DBA, 701 Brazos Street, Suite 1050, Austin, Texas 78701. 1 Case 2:08-cv-00260-DF Document 1 Filed 06/30/08 Page 2 of 7 3. Defendant BOSTON SCIENTIFIC SCIMED, INC. (“Scimed”) is a Minnesota corporation with its principal place of business at 1 Scimed Place, Maple Grove, Massachusetts 55311. Scimed can be served with process through its registered agent, Corporation Service Company, 380 Jackson Street, Suite 700, St. Paul, Minnesota 55101. Scimed is a wholly-owned subsidiary of Defendant BSC. 4. Defendant CORDIS CORPORATION (“Cordis”) is a Florida corporation with principal places of business at 14201 Northwest 60th Avenue, Miami Lakes, Florida 33014 and 33 Technology Drive, Warren, New Jersey 07059.
    [Show full text]
  • Koninklijke Philips N.V
    Deutsche Bank CORPORATE BANK Depositary Receipts Announcement July 08, 2020 KONINKLIJKE PHILIPS N.V. Please be advised of the following Final DR Stock Distribution information: Depositary Receipt Information CUSIP: 500472303 Contacts Country: Netherlands American Stock Transfer Dividend Type: Stock Tel: +1 (800) 821-8780 Ord Record Date: 01-Jul-20 DR Record Date: 01-Jul-20 Email: [email protected] Ord Payable Date: 07-Jul-20 DR Payable Date: 07-Jul-20 Corporate Actions Ord: DR Ratio: 1 : 1 Web: www.adr.db.com Gwen Minott +1-212-250-6182 Tax Rate: 0.00% Distribution Rate: 2.028516% (1 for 49.2971) Cash in Lieu Rate: $48.2429 Issuance Fee: $0.00 Cash in Lieu Payment Date: 7/9/2020 Koninklijke Philips N.V. maintains its proposed dividend of EUR 0.85 (USD 0.954082) per common share against the net income of 2019. The distribution of this dividend is in shares only, instead of the previously proposed distribution in cash or in shares, as approved at the Extraordinary General Meeting of shareholders held on June 26, 2020. Dividend in shares paid out of net income is in principle subject to a 15% dividend withholding tax, but only in respect of the par value of the shares (which value amounts to EUR 0.20 per share). Shareholders are advised to consult their tax advisor on the applicable situation with respect to taxes on the dividend received. On July 2, 2020 after close of trading on Euronext Amsterdam,the number of share dividend rights entitled to one new common share was determined based on the volume-weighted average price of all traded common shares Koninklijke Philips N.V.
    [Show full text]